Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., recently received the Drug Supplement Approval Notice from the National Medical Products Administration for lincomycin hydrochloride injection, confirming that the product has passed the generic drug consistency evaluation.

The medication is indicated for treating severe infections caused by susceptible strains such as streptococci, pneumococci, and staphylococci. However, it should only be used in patients who are allergic to penicillin or in cases where a physician determines that penicillin therapy is not appropriate.